Let’s be clear about one factor. Schrödinger (SDGR) isn’t an AI inventory. That’s what they emphatically advised us the final time we implied such a factor, and it’s admirable in an atmosphere the place each single firm is plastering “generative AI” throughout their investor decks in hopes of attracting extra {dollars}. What Schrödinger does is make the most of software program simulations to assist drug builders higher predict which novel molecules will efficiently go the FDA drug approval gauntlet. Their enterprise mannequin captures worth from software program licensing annual contracts (software program), and downstream royalties and milestone funds (drug discovery). After exhibiting robust double-digit development for the previous 5 years, Schrödinger could now see unfavorable development primarily based on the center of their 2024 steering.
And that coincides completely with our annual check-in with one of many 37 disruptive tech shares we’re presently holding.
Software program Development Stalls
The drop in income development is a priority, particularly contemplating that all over the place we glance software program is remodeling how corporations do enterprise. In SDGR’s year-end earnings name, the primary analyst out of the gate nailed it with a superb query. How ought to buyers take into consideration SDGR’s software program steering of 6% to 13% given a) the corporate’s previous robust income development and b) the current industry-wide AI momentum?
These questions are essential as a result of we are able to’t reply them trying
